Notably, it has been demonstrated that anti-CD46 mAbs targeting CD46 domain SCR1 do not block complement binding to CD4637, and are therefore potential congenital CMV therapeutics that can inhibit CMV infection while not inhibiting the CD46 complement inhibitory function. This evidence concerns the gene CD46 and cytomegalovirus infection.